Post-earnings recap
Reported
Tue, Aug 8, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
PTC Therapeutics reported a loss of $0.44 per share, which was better than expected, but the lack of revenue figures and guidance contributed to a 4.07% decline in stock price. Investors may be concerned about the company's future performance without clear financial targets. The focus on clinical trials indicates that the company is prioritizing long-term growth over short-term financial metrics.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.44 | N/A | +33.34% |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious outlook without providing detailed guidance. They emphasized their commitment to advancing their pipeline.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The focus remains on ongoing clinical trials and product development.